Nuvalent's NDA for Zidesamtinib Accepted by FDA, Targeting 2026 Launch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: Newsfilter
Nuvalent Inc's stock fell by 5.64% as it crossed below the 5-day SMA amid positive market conditions with the Nasdaq-100 and S&P 500 both up slightly.
The FDA has accepted Nuvalent's NDA for zidesamtinib, aimed at treating advanced ROS1-positive NSCLC patients, with a target action date of September 18, 2026. This marks a significant milestone for the company, potentially leading to its first commercial success. Additionally, Nuvalent plans to submit an NDA for neladalkib in the first half of 2026, further expanding its product portfolio. The company also reported a strong financial position with approximately $1.4 billion in cash, expected to fund operations into 2029, which supports its ongoing R&D efforts.
Despite the stock's decline, the acceptance of the NDA and the company's robust financial backing position Nuvalent favorably for future growth and product launches.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUVL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUVL
Wall Street analysts forecast NUVL stock price to rise
16 Analyst Rating
16 Buy
0 Hold
0 Sell
Strong Buy
Current: 123.500
Low
125.00
Averages
140.86
High
158.00
Current: 123.500
Low
125.00
Averages
140.86
High
158.00
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating LCI Industries (NYSE: LCII) for its sale to Patrick Industries, Inc., involving an exchange of 1.2440 shares per common share, potentially infringing on shareholder rights.
- Cash Acquisition Concerns: Nuvalent, Inc. (NASDAQ: NUVL) is being sold to GSK plc for $124.00 per share in cash, raising concerns about potential violations of shareholder rights in this transaction.
- Shareholder Equity in Merger: Dana Incorporated (NYSE: DAN) is set to be sold to Eaton Corporation plc, with Dana shareholders expected to own approximately 49.9% of the combined entity post-transaction, which may affect their control.
- Cash Transaction Impact: Taylor Morrison Home Corporation (NYSE: TMHC) is being sold to Berkshire Hathaway Inc. for $72.50 per common share in cash, which could significantly impact shareholder interests, prompting Halper Sadeh LLC to seek increased compensation and disclosures for shareholders.
See More
Investigation Alerts for Multiple Mergers
- Nuvalent Acquisition Investigation: Nuvalent is set to be acquired by GSK for $124 per share in a deal valued at $10.6 billion, with investigations focusing on whether the Nuvalent Board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Dana Merger Review: Dana will be acquired by Eaton in a transaction valued at approximately $5.1 billion, where Eaton shareholders will own at least 50.1% of the combined entity, raising concerns about whether Dana's Board ensured fair value for its shareholders.
- SUNation Merger Issues: SUNation Energy is merging with Suniva, resulting in pre-merger SUNation shareholders holding only about 1.8% of the combined company, with investigations questioning whether the Board conducted a fair process to protect shareholder interests.
- Taylor Morrison Acquisition Investigation: Taylor Morrison will be acquired by Berkshire Hathaway for $72.50 per share, totaling approximately $6.8 billion, with investigations into whether the Board fulfilled its fiduciary duties to ensure the fairness of the transaction for shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Nuvalent, Inc. (NASDAQ:NUVL) for potential violations of federal securities laws related to its sale to GSK plc for $124.00 per share in cash, indicating possible fiduciary breaches.
- Shareholder Rights: The firm encourages Nuvalent shareholders to contact them to discuss their rights and options at no cost, demonstrating a commitment to protecting investor interests.
- Additional Investigations: Furthermore, Halper Sadeh LLC is also scrutinizing Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) regarding its sale to Angelini Pharma S.p.A. for $31.50 per share in cash, which may similarly involve legal concerns.
- Legal Remedies: The firm may seek increased consideration, additional disclosures, or other relief on behalf of shareholders, highlighting its proactive role in safeguarding investor rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating companies such as Roku, Inc., Simulations Plus, Inc., Nuvalent, Inc., and Dana Incorporated for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights and interests.
- Roku Transaction Details: Roku, Inc. is in a deal with Fox Corporation at a price of $96.00 per share plus 0.9693 shares of Fox Class A common stock, which may limit the emergence of superior competing offers, thereby affecting shareholder options.
- Nuvalent Acquisition Situation: Nuvalent, Inc. is being acquired at $124.00 per share by GSK plc, a high acquisition price that may raise concerns regarding shareholder rights, especially given the potential limitations on other bids due to transaction terms.
- Dana Merger Impact: Dana Incorporated is merging with Eaton Corporation plc, with Dana shareholders expected to own approximately 49.9% of the combined company, a structure that may influence shareholder control and future financial performance.
See More
Investigation Alerts for Multiple Company Acquisitions
- Acquisition Overview: Arcosa, Inc. is set to be acquired by CRH for $150.00 per share in cash, with a total enterprise value of approximately $8.5 billion, and the investigation focuses on whether the board breached its fiduciary duties to shareholders.
- Fathom Holdings Acquisition: Fathom Holdings Inc. will be acquired by Bed Bath & Beyond, with an implied equity value of approximately $53.38 million, and the investigation concerns whether the board failed to conduct a fair process in the transaction.
- Nuvalent Acquisition Details: Nuvalent, Inc. will be acquired by GSK for $124.00 per share in cash, valuing the deal at $10.6 billion, with investigations into whether the board ensured fair value for shareholders.
- Dana Acquisition Transaction: Dana Incorporated will be acquired by Eaton Corporation in a deal valued at approximately $5.1 billion, with Eaton shareholders owning at least 50.1% of the combined company, and the investigation looks into the board's fiduciary duties to shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating AstroNova, Inc. (NASDAQ: ALOT) regarding its sale to Arcline Investment Management for $29.00 per share, which may infringe on shareholder rights.
- Shareholder Rights Protection: The firm encourages shareholders of both AstroNova and Nuvalent, Inc. (NASDAQ: NUVL), which is being sold for $124.00 per share, to understand their rights, as the terms may limit superior competing offers.
- Merger Transaction Review: The merger of Bio Green Med Solution, Inc. (NASDAQ: BGMS) with Future NRG Sdn. Bhd. is also under scrutiny, with Halper Sadeh LLC potentially seeking increased consideration or other remedies for shareholders.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, ensuring that affected shareholders can pursue their rights without upfront legal costs, demonstrating a strong commitment to investor protection.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating LCI Industries (NYSE: LCII) for its sale to Patrick Industries, Inc., involving an exchange of 1.2440 shares per common share, potentially infringing on shareholder rights.
- Cash Acquisition Concerns: Nuvalent, Inc. (NASDAQ: NUVL) is being sold to GSK plc for $124.00 per share in cash, raising concerns about potential violations of shareholder rights in this transaction.
- Shareholder Equity in Merger: Dana Incorporated (NYSE: DAN) is set to be sold to Eaton Corporation plc, with Dana shareholders expected to own approximately 49.9% of the combined entity post-transaction, which may affect their control.
- Cash Transaction Impact: Taylor Morrison Home Corporation (NYSE: TMHC) is being sold to Berkshire Hathaway Inc. for $72.50 per common share in cash, which could significantly impact shareholder interests, prompting Halper Sadeh LLC to seek increased compensation and disclosures for shareholders.
See More
Investigation Alerts for Multiple Mergers
- Nuvalent Acquisition Investigation: Nuvalent is set to be acquired by GSK for $124 per share in a deal valued at $10.6 billion, with investigations focusing on whether the Nuvalent Board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Dana Merger Review: Dana will be acquired by Eaton in a transaction valued at approximately $5.1 billion, where Eaton shareholders will own at least 50.1% of the combined entity, raising concerns about whether Dana's Board ensured fair value for its shareholders.
- SUNation Merger Issues: SUNation Energy is merging with Suniva, resulting in pre-merger SUNation shareholders holding only about 1.8% of the combined company, with investigations questioning whether the Board conducted a fair process to protect shareholder interests.
- Taylor Morrison Acquisition Investigation: Taylor Morrison will be acquired by Berkshire Hathaway for $72.50 per share, totaling approximately $6.8 billion, with investigations into whether the Board fulfilled its fiduciary duties to ensure the fairness of the transaction for shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Nuvalent, Inc. (NASDAQ:NUVL) for potential violations of federal securities laws related to its sale to GSK plc for $124.00 per share in cash, indicating possible fiduciary breaches.
- Shareholder Rights: The firm encourages Nuvalent shareholders to contact them to discuss their rights and options at no cost, demonstrating a commitment to protecting investor interests.
- Additional Investigations: Furthermore, Halper Sadeh LLC is also scrutinizing Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) regarding its sale to Angelini Pharma S.p.A. for $31.50 per share in cash, which may similarly involve legal concerns.
- Legal Remedies: The firm may seek increased consideration, additional disclosures, or other relief on behalf of shareholders, highlighting its proactive role in safeguarding investor rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating companies such as Roku, Inc., Simulations Plus, Inc., Nuvalent, Inc., and Dana Incorporated for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights and interests.
- Roku Transaction Details: Roku, Inc. is in a deal with Fox Corporation at a price of $96.00 per share plus 0.9693 shares of Fox Class A common stock, which may limit the emergence of superior competing offers, thereby affecting shareholder options.
- Nuvalent Acquisition Situation: Nuvalent, Inc. is being acquired at $124.00 per share by GSK plc, a high acquisition price that may raise concerns regarding shareholder rights, especially given the potential limitations on other bids due to transaction terms.
- Dana Merger Impact: Dana Incorporated is merging with Eaton Corporation plc, with Dana shareholders expected to own approximately 49.9% of the combined company, a structure that may influence shareholder control and future financial performance.
See More
Investigation Alerts for Multiple Company Acquisitions
- Acquisition Overview: Arcosa, Inc. is set to be acquired by CRH for $150.00 per share in cash, with a total enterprise value of approximately $8.5 billion, and the investigation focuses on whether the board breached its fiduciary duties to shareholders.
- Fathom Holdings Acquisition: Fathom Holdings Inc. will be acquired by Bed Bath & Beyond, with an implied equity value of approximately $53.38 million, and the investigation concerns whether the board failed to conduct a fair process in the transaction.
- Nuvalent Acquisition Details: Nuvalent, Inc. will be acquired by GSK for $124.00 per share in cash, valuing the deal at $10.6 billion, with investigations into whether the board ensured fair value for shareholders.
- Dana Acquisition Transaction: Dana Incorporated will be acquired by Eaton Corporation in a deal valued at approximately $5.1 billion, with Eaton shareholders owning at least 50.1% of the combined company, and the investigation looks into the board's fiduciary duties to shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating AstroNova, Inc. (NASDAQ: ALOT) regarding its sale to Arcline Investment Management for $29.00 per share, which may infringe on shareholder rights.
- Shareholder Rights Protection: The firm encourages shareholders of both AstroNova and Nuvalent, Inc. (NASDAQ: NUVL), which is being sold for $124.00 per share, to understand their rights, as the terms may limit superior competing offers.
- Merger Transaction Review: The merger of Bio Green Med Solution, Inc. (NASDAQ: BGMS) with Future NRG Sdn. Bhd. is also under scrutiny, with Halper Sadeh LLC potentially seeking increased consideration or other remedies for shareholders.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, ensuring that affected shareholders can pursue their rights without upfront legal costs, demonstrating a strong commitment to investor protection.
See More
